Addition of DMXAA (ASA404) to docetaxel in patients with hormone-refractory metastatic prostate cancer (HRMPC): update from a randomized, phase II study

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 5007-5007 ◽  
Author(s):  
R. Pili ◽  
M. Rosenthal
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Metastatic Prostate Cancer ◽  
Phase Ii Study ◽  
Randomized Phase Ii ◽  
Hormone Refractory

A randomized phase II study comparing bipolar androgen therapy vs. enzalutamide in asymptomatic men with castration resistant metastatic prostate cancer: The TRANSFORMER trial.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. TPS5079-TPS5079 ◽  
Author(s):  
Benjamin A. Teply ◽  
Emmanuel S. Antonarakis ◽  
Michael Anthony Carducci ◽  
Channing Judith Paller ◽  
Hao Wang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Metastatic Prostate Cancer ◽  
Phase Ii Study ◽  
Androgen Therapy ◽  
Castration Resistant ◽  
Randomized Phase Ii ◽  
Asymptomatic Men

Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting

2010 ◽  
Vol 40 (3) ◽  
pp. 201-208 ◽  
Author(s):  
S. Sewak ◽  
S. Kosmider ◽  
V. Ganju ◽  
A. Woollett ◽  
E. G. Yeow ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Metastatic Prostate Cancer ◽  
Phase Ii Study ◽  
Hormone Refractory
Sign in / Sign up

Export Citation Format

Share Document